NEW YORK, Jan 30 – CRS Robotics will supply automated protein expression platforms to MDS Proteomics of Toronto, Canada, for high-throughput screening of proteins, the companies announced Tuesday.
MDS proteomics is building an industrial-scale proteomics factory, where it uses proprietary bioinformatics technology and mass spectrometry to study protein function and protein-protein interactions. These robots will help MDS more fully automate its proteomics operations, the company said.
“CRS’s experience in high throughput screening and acknowledged leadership in automating difficult genomics protocols enabled it to consult on and offer the most up-to-date hardware and software solutions,” said Mark Pearson, senior vice president for research and bioinformatics at MDS.
Currently, MDS proteomics is jointly conducting mass spectrometry-based proteomic studies with Zyomyx, using Zyomyx’s protein chips and MDS’s protein pathway identification and analysis techniques.
MDS is also widely believed to be announcing a large-scale proteomics collaboration with IBM later Tuesday.